Richard mcfarland, ph.d., md
Richard McFarland, Ph.D., MD is the Chief Regulatory Officer Chief Regulatory Officer of ARMI/BioFabUSA. Prior to ARMI he was Associate Director of Policy for FDA/CBER’s Office of Tissues and Advanced Therapies and its predecessor office, the Office of Cellular, Tissue and Gene Therapies. In this position, he was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. Dr. McFarland received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas.